Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshio Ogino

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activatorsMakoto Ishikawa, Katsumasa Nonoshita, Yoshio Ogino, et al.
Endocrine Journal|April 21, 2007
Long-term remission of cyclic Cushing's disease that was diagnosed and treated surgically in non-active phaseShuichiro Asano, Hikaru Ooka, Ryo Okazaki, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonistsYoshio Ogino, Norikazu Ohtake, Yoshikazu Nagae, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivativesYoshio Ogino, Norikazu Ohtake, Yoshikazu Nagae, et al.
Communications Biology|June 10, 2022
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stressHiroyuki Ueno, Takuya Hoshino, Wakako Yano, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activatorsMakoto Ishikawa, Katsumasa Nonoshita, Yoshio Ogino, et al.
Endocrine Journal|April 21, 2007
Long-term remission of cyclic Cushing's disease that was diagnosed and treated surgically in non-active phaseShuichiro Asano, Hikaru Ooka, Ryo Okazaki, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonistsYoshio Ogino, Norikazu Ohtake, Yoshikazu Nagae, et al.
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivativesYoshio Ogino, Norikazu Ohtake, Yoshikazu Nagae, et al.
Communications Biology|June 10, 2022
TAS1553, a small molecule subunit interaction inhibitor of ribonucleotide reductase, exhibits antitumor activity by causing DNA replication stressHiroyuki Ueno, Takuya Hoshino, Wakako Yano, et al.
Pageof 2